Showing results (41-50 of 887) with videos related to
Sort By:
Pageof 89
Drugs in R&D|March 18, 2006
A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjectsKatelijn Decochez, Ronda K Rippley, Jutta L Miller, et al.Drugs in R&D|August 23, 2006
The melanocortin system as a therapeutic treatment target for adiposity and adiposopathyHarold BaysDrugs in R&D|August 23, 2006
Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788Drugs in R&D|April 11, 2025
Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug TherapyXiaolin Xu, Xueting Mao, Bo Liu, et al.Drugs in R&D|April 2, 2025
Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab BiosimilarHerve Bischoff, Neil K O'Connor, Jamie Kim, et al.Drugs in R&D|April 26, 2025
Bioequivalence and Safety of Two Amisulpride Formulations in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover StudyMin Wang, Yu Peng, Hegui Yan, et al.Drugs in R&D|December 13, 2012
Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteersSebastián Videla, Mounia Lahjou, Pascal Guibord, et al.Drugs in R&D|December 4, 2012
Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experienceDenis Leonardo Fontes Jardim, Débora de Melo Gagliato, Karina Braga Ribeiro, et al.Drugs in R&D|May 2, 2013
Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteersSebastián Videla, Jesús Cebrecos, Mounia Lahjou, et al.Drugs in R&D|November 24, 1999
Clinical potential of matrix metalloprotease inhibitorsS Wojtowicz-PragaPageof 89